Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Hepatitis C
Interventions: Ribavirin, Mericitabine, Peginterferon Alfa-2a, Placebo, Telaprevir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more

Conditions: Bacterial Infections
Interventions: XNW4107; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Ad26.RSV.preF, Fluarix, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Mt. Pleasant, South Carolina

Conditions: Migraine
Interventions: Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Femoroacetabular Impingement
Interventions: regional anesthesia bupivacaine, regional anesthesia placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Epstein Barr Virus (EBV) Infection
Interventions: MVA-BN-EBV, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Fulvestrant, Capivasertib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 818 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • Orange, California • San Francisco, California + 19 more

Conditions: Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
Interventions: Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo, Biosense Webster MyoStar NOGA Injection Catheter System; Drug · Device
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: SAR156597, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615; RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 115 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Lebrikizumab, Pirfenidone, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Rheumatoid Arthritis
Interventions: LY2127399, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 77
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Placebo, TAK-079; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: lunsekimig, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: La Jolla, California • Roseville, California • San Diego, California + 11 more

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 40
States / cities: Chandler, Arizona • San Diego, California • San Francisco, California + 36 more

Conditions: Healthy Volunteers
Interventions: USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo; Drug
Lead sponsor: US Biotest, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebos; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more

Conditions: Asthma
Interventions: IMA-638, placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 76
States / cities: Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 66 more

Conditions: Neuroma
Interventions: onabotulinum toxin type-A, placebo, 2nd phase - onabotulinum toxin type-A; Drug · Other
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: ESRD
Interventions: anakinra, actos, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hyperglycemia
Interventions: 5% dextrose, Vitamin C, Simvastatin, Sevoflurane; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 35 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Traumatic Brain Injury
Interventions: 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more

Search by objective public record fields.

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Regional Anesthesia in Hip Arthroscopy

Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Rheumatoid Arthritis Study in Participants

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

SAD and MAD Study of FTX-101 in Healthy Male Subjects

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Study of the Safety of USB005 in Healthy Volunteers

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma

Botulinum Toxin Type A for Neuroma Pain

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

Prehospital Tranexamic Acid Use for Traumatic Brain Injury